← Leaderboards
Johannes W.g. Vieweg
Duke University
$4,142,091
Attributed
$4,142,091
Total exposure
10
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $322.5K · FY2005–14$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$4,142,091 · 10
By mechanism
R01$2,394,021 · 2
K24$721,001 · 1
R21$558,400 · 1
K08$260,496 · 1
T32$123,900 · 1
M01$84,273 · 4
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- John H Sampson$43,413,436
- David Reardon$8,732,934
- Yiping Yang$13,692,641
- Duane A. Mitchell$34,257,734
- David M. Ashley$7,073,119
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer VaccineDendritic CellsHuman Therapy EvaluationClinical Trial Phase ICytotoxic T LymphocyteTransfectionRenal Cell CarcinomaMetastasisFlow CytometryProstate NeoplasmsPatient Oriented ResearchDrug Screening /EvaluationVaccine DevelopmentNeoplasm /Cancer ImmunologyEnzyme Linked Immunosorbent AssayTumor AntigensClinical TrialsAutologous TransplantationLeukocyte Activation /TransformationBiotechnologyHelper T Lymphocyte
Grant awards (26)
Training Program in Urologic Research$62,656
T32 · FY2014 · DK · contact PI
Training Program in Urologic Research$61,244
T32 · FY2013 · DK · contact PI
Elimination of Immature Myeloid Cells$154,500
K24 · FY2009 · CA · contact PI
Elimination of Immature Myeloid Cells$53,765
K24 · FY2009 · CA · contact PI
Elimination of Immature Myeloid Cells$153,883
K24 · FY2008 · CA · contact PI
Elimination of Immature Myeloid Cells$179,816
K24 · FY2007 · CA · contact PI
Elimination of Immature Myeloid Cells$179,037
K24 · FY2006 · CA · contact PI
Telomerase RNA Transfected Dendritic Cell Vaccines$284,296
R01 · FY2005 · CA
ACTIVE IMMUNOTHERAPY USING MATURE DC TRANSFECTED RNA ENCODING HTERT$15,691
M01 · FY2005 · RR
MATURED, RENAL TUMOR RNA-TRANSFECTED AUTOLOGOUS DENDRITIC CELLS$13,075
M01 · FY2005 · RR
ACTIVE IMMUNOTHERAPY USING LAMP HTERT RNA TRANSFECTED DC WITH OR WITHOUT DENILEU$9,415
M01 · FY2005 · RR
Telomerase RNA Transfected Dendritic Cell Vaccines$303,151
R01 · FY2004 · CA
Elimination of Regulatory T Cells$279,200
R21 · FY2004 · CA
IMMUNOTHERAPY WITH RENAL TUMOR RNA TRANSFECTED CELLS$237,174
R01 · FY2004 · CA
Immunotherapy Using Mature DC Transfected hTERT RNA$25,372
M01 · FY2004 · RR
Matured, Renal Tumor RNA-Transfected Dendritic Cells$20,720
M01 · FY2004 · RR
Telomerase RNA Transfected Dendritic Cell Vaccines$395,707
R01 · FY2003 · CA
Elimination of Regulatory T Cells$279,200
R21 · FY2003 · CA
IMMUNOTHERAPY WITH RENAL TUMOR RNA TRANSFECTED CELLS$220,420
R01 · FY2003 · CA
Telomerase RNA Transfected Dendritic Cell Vaccines$378,363
R01 · FY2002 · CA
IMMUNOTHERAPY WITH RENAL TUMOR RNA TRANSFECTED CELLS$281,099
R01 · FY2002 · CA
IMMUNOTHERAPY WITH RENAL TUMOR RNA TRANSFECTED CELLS$293,811
R01 · FY2001 · CA
IMMUNOTHERAPY OF PROSTATE CANCER WITH TUMOR VACCINES$130,248
K08 · FY2001 · CA
IMMUNOTHERAPY OF PROSTATE CANCER WITH TUMOR VACCINES$130,248
K08 · FY2000 · CA
Phase I safety &feasibility of immunotherapy in metastatic prostate carcinoma$0
M01 · FY2000 · RR
Phase I safety &feasibility of immunotherapy in metastatic prostate carcinoma$0
M01 · FY2000 · RR